New Pharmacological Treatment for Obstructive Sleep Apnea
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study will determine if mirtazapine, a unique antidepressant that does not disturb
sleep, will improve obstructive sleep apnea (OSA). The design is randomized, crossover,
double blind, and placebo controlled. On two consecutive nights of one week, the patients
receive either 30 mg mirtazapine or placebo at bedtime. The following week, the alternative
medication is administered. The patients have known mild to moderate sleep apnea. The
endpoints of the study are the apnea + hypopnea index (AHI), sleep quality, and the degree of
arterial oxygen desaturation.
Phase:
Phase 1
Details
Lead Sponsor:
US Department of Veterans Affairs VA Office of Research and Development